Zedira is a privately held clinical stage biotech company based in Darmstadt, Germany.

The Company focuses on disorders linked to the enzyme family of transglutaminases.

Zedira’s business model is focused on the development of small molecule drug candidates for early licensing.
Zedira’s drug candidate for celiac disease therapy, tissue transglutaminase (TG2) blocker ZED1227 is currently tested in phase 2a clinical trials.

ZED1227 is licensed to Dr. Falk Pharma for Europe and four other countries. Dr. Falk Pharma took over responsibility for preclinical and clinical development as well as for approval and marketing of the drug.

Current internal development work focuses on second generation TG2 inhibitors optimized for systemic indications. Zedira medicinal chemists discovered a novel class of reversible-acting blockers combining high potency along with excellent selectivity. Zedira taps the potential of these oral bio available compounds to address systemic indications, especially fibrotic disorders (e.g. diabetic nephropathy).

Further, Zedira developed coagulation FXIIIa blockers (F13a, plasma transglutaminase) for safe anticoagulation (thromboprophylaxis). This unique and promising approach has the potential of a significant reduction in the life-threatening tendency to bleeding as provoked by current drugs.

In a rabbit animal model, Zedira already showed the proof of principle of “safe” anticoagulation therapy by inhibition of Factor XIIIa.

The Company’s management is open to considering investment by private individuals and institutions.
Please do not hesitate to contact us if you are interested in an attractive opportunity.

Zedira’s managing partners, Dr. Martin Hils and Dr. Ralf Pasternack, will be pleased to be at your disposal:

Phone:      +49 6151 3251-00 or
E-mail:      contact@zedira.com

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events